The digital transformation of pharmaceutical enterprises is imperative as big data weaves Technology Network

[pharmaceutical network industry trends] drug development and innovation is a long cycle, high investment and high risk process It is reported that the development of a drug usually takes 10 to 15 years, and the investment will reach 500 million to 1 billion US dollars These problems hinder the development of drug innovation However, through digital transformation, it can shorten the research and development cycle of drugs, reduce risks and save costs At present, some digital technologies have been integrated into medical research, such as sensor technology, wearable health device technology, mobile monitoring technology, etc if these technologies are used in the process of drug clinical trials and clinical development, the process and mode of drug development will be further changed in the future The industry believes that new technologies such as artificial intelligence, big data, Internet medicine and Internet of things are widely used in the pharmaceutical industry, and the digital transformation of enterprises is imperative In fact, in order to realize digital transformation and promote drug development and innovation, many local pharmaceutical enterprises have chosen to cooperate with internal and external enterprises It is reported that the two sides will jointly build a private DMP data management platform for the first brand of a large domestic central pharmaceutical enterprise, and comprehensively open the digital transformation road for local pharmaceutical enterprises Nequal enyike will provide comprehensive digital strategic planning consulting services for the digital strategy of Cr 39 At the same time, nequal enyike will combine data products and technologies to connect and connect the online and offline full contact pharmaceutical enterprise consumer data, and realize the intelligent management and closed-loop application of one-stop enterprise marketing data Due to the particularity of the pharmaceutical industry, Cr Sanjiu said that it adheres to the attitude and requirements of innovation, preciseness, openness and steady progress in the digital transformation JINGDING pharmaceutical has cooperated with Microsoft and datavant successively In October 2017, JINGDING pharmaceutical and Microsoft jointly established a technology development alliance, and then jointly launched the perception cloud platform The platform integrates JINGDING pharmaceutical's comprehensive industry and professional knowledge and innovative technical solutions with Microsoft's intelligent cloud services, as well as investment in global compliance certification and enterprise level security services In September 2018, JINGDING pharmaceutical entered into strategic cooperation with datavant, a healthcare technology company, to help improve the process of drug development and commercialization by linking real world data and clinical trial data from different sources UL and smart software signed a contract Smart software has rich application experience in the pharmaceutical and medical industry Recently, UL signed a contract to become an important partner on the way of digital innovation It is reported that in the future, both sides will work together to create a benchmark for digital transformation of Chinese pharmaceutical enterprises
In addition to these cases, more pharmaceutical enterprises are planning digital innovation strategies Through cooperation, it is conducive to integrating various technological and resource advantages, exerting their strength, so as to improve the competitiveness, flexibility, product life cycle, manufacturing and operation speed and production efficiency of enterprises, and promote innovation and enhance enterprise value According to the industry, the purpose of digital transformation is to promote the realization of more, more flexible and flexible drug production, and to benefit enterprises and patients However, in the process of laying out the digital strategy, pharmaceutical equipment enterprises need to consider the risk factors, to be more suitable for production and closer to users, to quickly provide customers with complete solutions by reducing complexity.